These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 11241875)
21. Dopamine D Salami A; Garrett DD; Wåhlin A; Rieckmann A; Papenberg G; Karalija N; Jonasson L; Andersson M; Axelsson J; Johansson J; Riklund K; Lövdén M; Lindenberger U; Bäckman L; Nyberg L J Neurosci; 2019 Jan; 39(3):537-547. PubMed ID: 30478031 [TBL] [Abstract][Full Text] [Related]
22. A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory. Gibbs SE; D'Esposito M Neuroscience; 2006 Apr; 139(1):359-71. PubMed ID: 16458442 [TBL] [Abstract][Full Text] [Related]
23. Tyrosine depletion alters cortical and limbic blood flow but does not modulate spatial working memory performance or task-related blood flow in humans. Ellis KA; Mehta MA; Naga Venkatesha Murthy PJ; McTavish SF; Nathan PJ; Grasby PM Hum Brain Mapp; 2007 Nov; 28(11):1136-49. PubMed ID: 17290373 [TBL] [Abstract][Full Text] [Related]
24. An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. Vytlacil J; Kayser A; Miyakawa A; D'Esposito M PLoS One; 2014; 9(1):e87109. PubMed ID: 24498023 [TBL] [Abstract][Full Text] [Related]
25. Effects of bromocriptine on human subjects depend on working memory capacity. Kimberg DY; D'Esposito M; Farah MJ Neuroreport; 1997 Nov; 8(16):3581-5. PubMed ID: 9427330 [TBL] [Abstract][Full Text] [Related]
26. Modulation of inhibition of return by the dopamine D2 receptor agonist bromocriptine depends on individual DAT1 genotype. Rokem A; Landau AN; Prinzmetal W; Wallace DL; Silver MA; D'Esposito M Cereb Cortex; 2012 May; 22(5):1133-8. PubMed ID: 21799208 [TBL] [Abstract][Full Text] [Related]
27. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119 [TBL] [Abstract][Full Text] [Related]
28. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Luciana M; Collins PF; Depue RA Cereb Cortex; 1998; 8(3):218-26. PubMed ID: 9617916 [TBL] [Abstract][Full Text] [Related]
29. Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Martorana A; Di Lorenzo F; Esposito Z; Lo Giudice T; Bernardi G; Caltagirone C; Koch G Neuropharmacology; 2013 Jan; 64():108-13. PubMed ID: 22863599 [TBL] [Abstract][Full Text] [Related]
30. New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line. Pornour M; Ahangari G; Hejazi SH; Deezagi A Recent Pat Anticancer Drug Discov; 2015; 10(2):214-23. PubMed ID: 25876608 [TBL] [Abstract][Full Text] [Related]
31. Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Wilkinson LS; Dias R; Thomas KL; Augood SJ; Everitt BJ; Robbins TW; Roberts AC Neuroscience; 1997 Oct; 80(3):717-30. PubMed ID: 9276488 [TBL] [Abstract][Full Text] [Related]
32. Spontaneous Eye Blink Rate (EBR) Is Uncorrelated with Dopamine D2 Receptor Availability and Unmodulated by Dopamine Agonism in Healthy Adults. Dang LC; Samanez-Larkin GR; Castrellon JJ; Perkins SF; Cowan RL; Newhouse PA; Zald DH eNeuro; 2017; 4(5):. PubMed ID: 28929131 [TBL] [Abstract][Full Text] [Related]
33. Dopaminergic modulation of neuronal activity in the monkey putamen through D1 and D2 receptors during a delayed Go/Nogo task. Inase M; Li BM; Tanji J Exp Brain Res; 1997 Nov; 117(2):207-18. PubMed ID: 9419068 [TBL] [Abstract][Full Text] [Related]
34. Effects of tolcapone and bromocriptine on cognitive stability and flexibility. Cameron IGM; Wallace DL; Al-Zughoul A; Kayser AS; D'Esposito M Psychopharmacology (Berl); 2018 Apr; 235(4):1295-1305. PubMed ID: 29427081 [TBL] [Abstract][Full Text] [Related]
35. Dopamine D2 receptor as a cellular component controlling nocturnal hyperactivities in Drosophila melanogaster. Lee G; Kikuno K; Bahn JH; Kim KM; Park JH Chronobiol Int; 2013 May; 30(4):443-59. PubMed ID: 23286280 [TBL] [Abstract][Full Text] [Related]
36. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex. Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291 [TBL] [Abstract][Full Text] [Related]
37. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. Schwartz SS; Zangeneh F Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683 [TBL] [Abstract][Full Text] [Related]
38. Dopamine and memory dedifferentiation in aging. Abdulrahman H; Fletcher PC; Bullmore E; Morcom AM Neuroimage; 2017 Jun; 153():211-220. PubMed ID: 25800211 [TBL] [Abstract][Full Text] [Related]
40. Effects of agonists and antagonists of D1 and D2 dopamine receptors on self-stimulation of the medial prefrontal cortex in the rat. Ferrer JM; Sanguinetti AM; Vives F; Mora F Pharmacol Biochem Behav; 1983 Aug; 19(2):211-7. PubMed ID: 6138775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]